Elsevier

Journal of Hepatology

Volume 65, Issue 4, October 2016, Pages 862-864
Journal of Hepatology

Letter to the Editor
Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment

https://doi.org/10.1016/j.jhep.2016.05.034Get rights and content

Section snippets

Conflict of interest

Harrys A. Torres is or has been the principal investigator for studies funded by Gilead Sciences, Merck & Co., Inc., and Vertex Pharmaceuticals, with all funds paid to The University of Texas MD Anderson Cancer Center. He also is or has been a paid scientific advisor for Gilead Sciences, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Vertex Pharmaceuticals, Genentech, Novartis, Astellas Pharma, Pfizer Inc., and Theravance Biopharma, Inc. The terms of these arrangements are managed by MD

Acknowledgements

We thank Don Norwood for editorial assistance.

References (6)

There are more references available in the full text version of this article.

Cited by (0)

View full text